The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19.
作者信息
Gozzetti Alessandro, Capochiani Enrico, Bocchia Monica
机构信息
Division of Hematology, University of Siena, Siena, Italy.
Hematology Unit, Center for Translational Medicine, Azienda USL Toscana NordOvest, Livorno, Italy.
出版信息
Leukemia. 2020 Oct;34(10):2815-2816. doi: 10.1038/s41375-020-01038-8. Epub 2020 Sep 2.
Abstract
摘要
相似文献
1
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19.
Leukemia. 2020 Oct;34(10):2815-2816. doi: 10.1038/s41375-020-01038-8. Epub 2020 Sep 2.
2
Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS).
Leukemia. 2020 Aug;34(8):2276-2278. doi: 10.1038/s41375-020-0907-9. Epub 2020 Jun 17.
3
Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation.
Leukemia. 2020 Jul;34(7):1723-1725. doi: 10.1038/s41375-020-0898-6. Epub 2020 Jun 11.
4
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
Cytokine Growth Factor Rev. 2020 Aug;54:51-62. doi: 10.1016/j.cytogfr.2020.06.013. Epub 2020 Jun 20.
5
Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19.
J Am Acad Dermatol. 2020 Jul;83(1):e67-e68. doi: 10.1016/j.jaad.2020.04.097. Epub 2020 Apr 25.
6
Selective inhibition of thromboinflammation in COVID-19 by Btk inhibitors.
Platelets. 2020 Nov 16;31(8):989-992. doi: 10.1080/09537104.2020.1809647. Epub 2020 Sep 6.
7
How COVID-19 affects patients receiving anticytokine and JAK inhibitors in rheumatology and dermatology.
Immunotherapy. 2020 Oct;12(15):1115-1119. doi: 10.2217/imt-2020-0153. Epub 2020 Jul 9.
8
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
Br J Haematol. 2020 Jul;190(2):e73-e76. doi: 10.1111/bjh.16863. Epub 2020 Jun 4.
9
The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
J Am Acad Dermatol. 2020 Jun;82(6):e223-e226. doi: 10.1016/j.jaad.2020.03.099. Epub 2020 Apr 9.
10
JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk.
Eur Respir J. 2020 Sep 24;56(3). doi: 10.1183/13993003.01919-2020. Print 2020 Sep.
引用本文的文献
1
Comparative Evaluation of GS-441524, Teriflunomide, Ruxolitinib, Molnupiravir, Ritonavir, and Nirmatrelvir for In Vitro Antiviral Activity against Feline Infectious Peritonitis Virus.
Vet Sci. 2023 Aug 9;10(8):513. doi: 10.3390/vetsci10080513.
2
Patho-Physiology of Aging and Immune-Senescence: Possible Correlates With Comorbidity and Mortality in Middle-Aged and Old COVID-19 Patients.
Front Aging. 2021 Dec 16;2:748591. doi: 10.3389/fragi.2021.748591. eCollection 2021.
3
Severe COVID-19 Shares a Common Neutrophil Activation Signature with Other Acute Inflammatory States.
Cells. 2022 Mar 1;11(5):847. doi: 10.3390/cells11050847.
4
Impaired JAK-STAT pathway signaling in leukocytes of the frail elderly.
Immun Ageing. 2022 Jan 17;19(1):5. doi: 10.1186/s12979-021-00261-w.
5
TextEssence: A Tool for Interactive Analysis of Semantic Shifts Between Corpora.
Proc Conf. 2021 Jun;2021:106-115.
6
COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.
Cytokine Growth Factor Rev. 2021 Aug;60:28-45. doi: 10.1016/j.cytogfr.2021.03.006. Epub 2021 Apr 14.
7
Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome.
Front Pharmacol. 2021 Apr 22;12:650295. doi: 10.3389/fphar.2021.650295. eCollection 2021.
8
Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
Clin Microbiol Rev. 2021 May 12;34(3). doi: 10.1128/CMR.00299-20. Print 2021 Jun 16.
9
Potential therapeutic and pharmacological strategies for SARS-CoV2.
J Pharm Investig. 2021;51(3):281-296. doi: 10.1007/s40005-021-00520-4. Epub 2021 Mar 5.
10
Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections?
Front Physiol. 2021 Jan 12;11:571416. doi: 10.3389/fphys.2020.571416. eCollection 2020.
本文引用的文献
1
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
Leukemia. 2020 Jul;34(7):1805-1815. doi: 10.1038/s41375-020-0891-0. Epub 2020 Jun 9.
Zotero 插件